Evidence map›Paper›PMID 32075936›Full record

ArticleJournal of virology2020

Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission.

Laura E Doepker, Cassandra A Simonich, Duncan Ralph, Mackenzie M Shipley, Meghan Garrett, Theodore Gobillot, Vladimir Vigdorovich, D Noah Sather, Ruth Nduati, Frederick A Matsen and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Laura E DoepkerHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Cassandra A SimonichHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Duncan RalphDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Mackenzie M ShipleyHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Meghan GarrettHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Theodore GobillotHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Vladimir VigdorovichCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
D Noah SatherCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Ruth NduatiDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Frederick A MatsenDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Julie M OverbaughHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA joverbau@fredhutch.org.
Fred Hutch Cancer Center · USUniversity of Washington · USInfectious Disease Research Institute · USUniversity of Nairobi · KE

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
DEFINING THE INFANT IMMUNE RESPONSE TO HIVR01AI120961 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2016 to 2020
$4.1M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
Defining the Prevalence and Viral Genetics of Zika Virus in KenyaF30AI142870 · NIAID · UNIVERSITY OF WASHINGTON · PI GOBILLOT, THEODORE AUGUST · 2019 to 2021
$131k
Characterizing broadly neutralizing antibody responses of HIV-1-infected infantsF30AI122866 · NIAID · UNIVERSITY OF WASHINGTON · PI SIMONICH, CASSANDRA ARIEN LYNN · 2016 to 2018
$125k
Howard Hughes Medical InstituteNIAID NIH HHS F30 AI122866NIAID NIH HHS F30 AI142870NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI120961NIAID NIH HHS T32 AI007140NIGMS NIH HHS T32 GM007266NIH HHS S10 OD020069
6 · The paper itself

Abstract

Infants of HIV-positive mothers can acquire HIV infection by various routes, but even in the absence of antiviral treatment, the majority of these infants do not become infected. There is evidence that maternal antibodies provide some protection from infection, but gestational maternal antibodies have not yet been characterized in detail. One of the most studied vertically infected infants is BG505, as the virus from this infant yielded an Envelope protein that was successfully developed as a stable trimer. Here, we isolated and characterized 39 HIV-specific neutralizing monoclonal antibodies (nAbs) from MG505, the mother of BG505, at a time point just prior to vertical transmission. These nAbs belonged to 21 clonal families and employed a variety of VH genes. Many were specific for the HIV-1 Env V3 loop, and this V3 specificity correlated with measurable antibody-dependent cellular cytotoxicity (ADCC) activity. The isolated nAbs did not recapitulate the full breadth of heterologous or autologous virus neutralization by contemporaneous plasma. Notably, we found that the V3-targeting nAb families neutralized one particular maternal Env variant, even though all tested variants had low V3 sequence diversity and were measurably bound by these nAbs. None of the nAbs neutralized BG505 transmitted virus. Furthermore, the MG505 nAb families were found at relatively low frequencies within the maternal B cell repertoire; all were less than 0.25% of total IgG sequences. Our findings illustrate an example of the diversity of HIV-1 nAbs within one mother, cumulatively resulting in a collection of antibody specificities that can contribute to the transmission bottleneck.

Indexed as

AIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingAntibody Specificityenv Gene Products, Human Immunodeficiency VirusEpitopesFemaleHIV-1HIV AntibodiesHIV InfectionsHumansInfantInfectious Disease Transmission, VerticalPregnancyPregnancy Complications, InfectiousAIDS VaccinesAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodiesantibody functionhuman immunodeficiency virusmaternal antibodiesmonoclonal antibodiesmother-to-child transmission

Identifiers

PMID32075936
PMCPMC7163126
OpenAlexW3007156177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.